Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements, Volume 1: Main Report
Abstract
A series of technical problems has delayed FDA approval for BioPort Corporation to deliver anthrax vaccine adsorbed (AVA) to the DoD. BioPort is preparing for a new FDA review, and the DoD is providing both financial relief and technical assistance to augment BioPort's efforts. Under this strategy, the earliest BioPort could gain FDA approval and resume AVA delivery is late May 2001. A more realistic expectation is delivery in the first half of 2002. IDA and the RAND Corporation studied the advantages and disadvantages of the DoD purchasing BioPort's Lansing, Michigan, AVA-production facility and converting it to a government-owned, contractor-operated (GOCO) operation. In one scenario, the DoD would select a new company to run the facility; in another, the DoD would have BioPort run the facility. We found that neither Option would result in vaccine being delivered faster than under the current strategy. Under the first GOCO scenario, the earliest AVA could be delivered would be 2003 (more probably late 2004). Under the second scenario, the earliest delivery date would be August 2001 (more probably late 2002). This report is the first of two volumes.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA388211
Entities
People
- Alec W. Salerno
- John J. Cloos
- John W. Bailey
- Maria Borga
- Thomas P. Frazier
Organizations
- Institute for Defense Analyses